Cepheid selected as national collaborator in U.S. public health emergency response
Cepheid has been chosen by the CDC as a national collaborator to fast-track the development and deployment of rapid diagnostic tests during health emergencies, leveraging early access to outbreak data and samples.
Cepheid announced that it has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators under a new federal initiative designed to accelerate the development and deployment of rapid diagnostic technologies during public health emergencies. The award was issued under a multiple-award Indefinite Delivery-Indefinite Quantity (IDIQ) contract.
Through this collaboration, CDC can provide Cepheid with early access to outbreak samples, genomic sequences, and critical reference materials. This access aims to help close development gaps during early pathogen emergence and accelerate the creation of next-generation diagnostic assays, ensuring that rapid, accurate testing can be deployed quickly when new threats arise.
As part of this multi-award IDIQ framework, Cepheid will contribute to a coordinated national effort to modernize outbreak detection, accelerate diagnostic innovation, and ensure testing remains agile in the face of evolving threats. This collaboration underscores the importance of public-private partnerships for rapid scaling, scientific advancement, and operational readiness.
